Fennec Pharmaceuticals, Inc. (FRX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Fennec Pharmaceuticals, Inc. (FRX)
Company Performance

Current Price

as of Oct 16, 2024

$4.64

P/E Ratio

132.16

Market Cap

$126.46M

Description

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Metrics

Overview

  • HQDurham, NC
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerFRX
  • Price$4.640926+0.58%

Trading Information

  • Market Cap$126.46M
  • Float74.14%
  • Average Daily Volume (1m)4,119
  • Average Daily Volume (3m)2,416
  • EPS$0.13

Company

  • Revenue$66.16M
  • Rev Growth (1yr)122.51%
  • Net Income-$7.60M
  • Gross Margin91.63%
  • EBITDA Margin-69.39%
  • EBITDA-$6.89M
  • EV$211.66M
  • EV/Revenue3.20
  • P/E132.16
  • P/S2.63
  • P/BN/A
Documents